Start › Rak płaskonabłonkowy głowy i szyi › Massachusetts › Boston
Badania kliniczne dla Rak płaskonabłonkowy głowy i szyi w mieście Boston, MA
40 badań dla Rak płaskonabłonkowy głowy i szyi szuka uczestników w ośrodkach w mieście Boston i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekrutacjaFaza 1
- Massachusetts General Hospital, Boston
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RekrutacjaFaza 2/3
- Site #0131, Boston
- Site#0101, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekrutacjaFaza 1
- Exelixis Clinical Site #7, Boston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RekrutacjaFaza 3
- Boston Medical Center, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RekrutacjaFaza 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RekrutacjaFaza 1
- Research Site, Boston
- Research Site, Boston
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RekrutacjaFaza 3
- Dana Farber Cancer Institute, Boston
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
RekrutacjaFaza 1/2
- Dana Farber Cancer Institute, Boston
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RekrutacjaFaza 3
- Boston Medical Center, Boston
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 1
- Boston Medical Center, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekrutacjaFaza 1/2
- Tufts Medical Center, Boston
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 2
- Tufts Medical Center, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekrutacjaFaza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RekrutacjaFaza 1/2
- Massachusetts General Hospital, Boston
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RekrutacjaFaza 2
- Tufts Medical Center, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
RekrutacjaFaza 1
- Massachusetts General Hospital, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RekrutacjaBadanie obserwacyjne
- Dana Farber Cancer Institute, Boston
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RekrutacjaFaza 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RekrutacjaFaza 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RekrutacjaFaza 2
- Boston Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RekrutacjaFaza 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
PDT For Induction Therapy For Head And Neck Cancer
RekrutacjaFaza 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekrutacjaFaza 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- i 2 więcej
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
RekrutacjaFaza 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RekrutacjaFaza 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekrutacjaFaza 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Dana-Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
RekrutacjaFaza 1
- Dana Farber Cancer Institute, Boston
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
RekrutacjaFaza 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
RekrutacjaWczesna faza 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RekrutacjaFaza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RekrutacjaFaza 1/2
- Dana Farber Cancer Institute, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RekrutacjaFaza 1
- Dana Farber/Partners Cancer Care Inc, Boston
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
RekrutacjaBadanie obserwacyjne
- Massachusetts Eye and Ear, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RekrutacjaFaza 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RekrutacjaFaza 2
- Dana Farber Cancer Institute, Boston
Badania dla Rak płaskonabłonkowy głowy i szyi w innych miastach
- Houston, TX47 badań
- Los Angeles, CA42 badań
- New York City, NY39 badań
- Nashville, TN39 badań
- St. Louis, MO28 badań
- Arlington, VA26 badań
- Philadelphia, PA26 badań
- Chicago, IL26 badań
- Atlanta, GA24 badań
- San Antonio, TX22 badań
- New Haven, CT22 badań
- Pittsburgh, PA22 badań
Inne badania w mieście Boston
- Rak piersi112 badań
- Niedrobnokomórkowy rak płuca90 badań
- Nowotwory (wszystkie typy)85 badań
- Nowotwór przerzutowy63 badań
- Rak jelita grubego i odbytnicy63 badań
- Rak płuc62 badań
- Rak jajnika61 badań
- Rak prostaty59 badań
- Depresja52 badań
- Rak endometrium50 badań
- Niewydolność serca44 badań
- Ostra białaczka szpikowa44 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.